(19)
(11) EP 1 537 114 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.10.2007 Bulletin 2007/40

(45) Mention of the grant of the patent:
09.08.2006 Bulletin 2006/32

(21) Application number: 03784194.7

(22) Date of filing: 06.08.2003
(51) International Patent Classification (IPC): 
C07D 487/04(2006.01)
A61K 31/5517(2006.01)
C07D 487/04(2006.01)
C07D 235/00(2006.01)
C07D 243/00(2006.01)
 A61K 31/519(2006.01)
A61P 5/40(2006.01)
C07D 241/00(2006.01)
C07D 487/04(2006.01)
C07D 235/00(2006.01)
(86) International application number:
PCT/EP2003/008720
(87) International publication number:
WO 2004/014914 (19.02.2004 Gazette 2004/08)

(54)

ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS

ORGANISCHE VERBINDUNGEN ALS MITTEL ZUR BEHANDLUNG VON ALDOSTERONBEDINGTEN ZUSTÄNDEN

COMPOSES ORGANIQUES SERVANT D'AGENTS POUR LE TRAITEMENT D'ETATS PATHOLOGIQUES INDUITS PAR L'ALDOSTERONE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 07.08.2002 US 401693 P

(43) Date of publication of application:
08.06.2005 Bulletin 2005/23

(73) Proprietors:
  • Novartis AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventor:
  • MC KENNA, Jeffrey
    San Diego, CA 92111 (US)

(74) Representative: de Weerd, Petrus G.W. et al
Novartis International AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)


(56) References cited: : 
WO-A-97/00257
   
  • YAMAUCHI, MASAHIGE ET AL: "Reactivity of 2,4(5)-dialkylimidazoles. Synthesis of 6,7,8,9-tetrahydro- 5H-imidazo[1,5-a][1,4]diazepine derivatives" CHEMICAL & PHARMACEUTICAL BULLETIN (1976), 24(7), 1480-4 , XP009019004
  • YAMAUCHI, MASASHIGE ET AL: "Synthesis of 6,7,8,9-tetrahydro-5H-imidazo[1,5-a][1,4]d iazepines" CHEMISTRY & INDUSTRY (LONDON, UNITED KINGDOM) (1976), (1), 31-2 , XP009019005
  • JANIN Y L ET AL: "Imidazo[1,5-g][1,4]diazepines, TIBO Analogues Lacking the Phenyl Ring: Synthesis and Evaluation as Anti-HIV Agents" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 52, no. 48, 25 November 1996 (1996-11-25), pages 15157-15170, XP004105102 ISSN: 0040-4020
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).